Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 3/20 | 0.61 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722051 | 0.90 | ABCC8 (0.48) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL718758 | 0.89 | ABCC8 (0.58) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL719662 | 0.87 | ABCC8 (0.56) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL721297 | 0.87 | ABCC8 (0.56) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL7944270 | 0.86 | ABCC8 (0.54) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL717822 | 0.86 | CYP3A4 (0.42) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL7957631 | 0.85 | ABCC8 (0.57) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL7944181 | 0.85 | ABCC8 (0.53) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL7952483 | 0.85 | ABCC8 (0.53) | ABCC8KCNJ11THRBALDH1A1CYP1A2 | |
| SCHEMBL7952438 | 0.85 | ABCC8 (0.53) | ABCC8KCNJ11THRBALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802313-A2 | THERAPEUTIC AGENTS TRAGETING THE NCCA-ATP CHANNEL AND METHODS OF USE THEREOF | University of Maryland, Baltimore (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006036278-A2 | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-04-06 | — | — | WO | claimed |
| CN-1222910-A | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 1999-07-14 | — | — | CN | claimed |
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-03-30 | — | — | US | disclosed |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| US-20200163902-A1 | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-05-28 | — | — | US | disclosed |
| US-10583094-B2 | Therapeutic methods that target the NCCA-ATP channel | UNIVERSITY OF MARYLAND (US) | 2020-03-10 | — | — | US | disclosed |
| US-20170112860-A1 | NOVEL NON-SELECTIVE CATION CHANNEL IN NEURONAL CELLS AND METHODS FOR TREATING BRAIN SWELLING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | disclosed |
| EP-1802313-A2 | THERAPEUTIC AGENTS TRAGETING THE NCCA-ATP CHANNEL AND METHODS OF USE THEREOF | University of Maryland, Baltimore (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20060276411-A1 | Novel non-selective cation channel in neuronal cells and methods for treating brain swelling | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006036278-A2 | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-04-06 | — | — | WO | disclosed |
| CN-1081633-C | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 2002-03-27 | — | — | CN | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
| CN-1222910-A | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 1999-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC8 605/4885KCNJ11 24/4885THRB 732/4885 |
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | ABCC8 62/4885KCNJ11 3/4885THRB 3078/4885 |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | ABCC8 62/4885KCNJ11 3/4885THRB 3078/4885 |
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | ABCC8 62/4885KCNJ11 3/4885THRB 3078/4885 |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | ABCC8 62/4885KCNJ11 3/4885THRB 3078/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | ABCC8 62/4885KCNJ11 3/4885THRB 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.